Butterfly Network (NYSE:BFLY) shares climbed 17% on Thursday after Midjourney revealed a new medical imaging platform powered by Butterfly’s Ultrasound-on-Chip technology, highlighting a potentially significant new commercial application for the company’s semiconductor-based ultrasound platform.
The announcement came during a launch event in San Francisco, where Midjourney introduced its new healthcare division, Midjourney Medical, alongside a flagship imaging system known as the Midjourney Scanner.
Midjourney Expands Into Healthcare Technology
The Midjourney Scanner represents the company’s first major move into healthcare hardware and is designed to transform ultrasound imaging into a large-scale computational tomography platform.
The system incorporates Butterfly’s licensed Ultrasound-on-Chip technology and combines it with advanced image reconstruction software and hyperscale computing resources.
According to information presented by Midjourney, the platform utilizes hundreds of thousands of ultrasonic elements to generate high-resolution three-dimensional full-body scans in approximately one minute.
Consumer-Focused Health Strategy Takes Shape
Midjourney also outlined plans to launch a flagship wellness spa in San Francisco, where the first Midjourney Scanner will be deployed.
The strategy points toward a consumer-oriented healthcare model, offering full-body imaging as part of a broader health and wellness service.
The company is reportedly developing four hardware products in total, consisting of two handheld devices and two larger imaging systems.
Technology Opens New Opportunities for Butterfly
The development attracted attention from analysts, who noted that the initiative demonstrates the broader potential of Butterfly’s semiconductor ultrasound technology beyond its traditional handheld imaging products.
TD Cowen analyst Joshua Jennings said the launch underscores the potentially underappreciated value of Butterfly’s Ultrasound-on-Chip platform and highlights its ability to serve as the foundation for entirely new imaging applications.
According to Jennings, the collaboration could strengthen the case for BFLY Embedded, validating Butterfly’s technology as a licensable infrastructure platform capable of generating future licensing fees, chip sales and potential revenue-sharing opportunities.
Investors Await Management Commentary
Butterfly management is expected to provide additional insight into the initiative during a conference call hosted by TD Cowen.
Chief Executive Officer Joe DeVivo, Chief Financial Officer John Doherty and Senior Vice President of Innovation David Horsley are scheduled to discuss the partnership and its implications for Butterfly’s long-term business strategy.
The market reaction suggests investors view the Midjourney announcement as a potentially important step in expanding Butterfly’s addressable market beyond point-of-care ultrasound and into next-generation imaging infrastructure.